March 14, 2025

FDA Warns Doctors of Nitrous Oxide Misuse

The FDA warns of serious health risks associated with non-medical use of nitrous oxide, highlighting neurological damage, thromboembolic events, and death.

Reuters

March 14, 2025

FDA Recommends Influenza Vaccine Strains for 2025 to 2026

The FDA has selected influenza vaccine strains for the 2025 to 2026 U.S. flu season, maintaining consistency with prior formulations while incorporating updated epidemiologic and antigenic data to optimize protection.

Conexiant

March 13, 2025

FDA Chief Counsel Resigns Two Days In

U.S. FDA's chief counsel resigns amidst controversy surrounding her appointment and connections to mifepristone during the Biden administration.

Reuters

March 11, 2025

First State to Ban Fluoride in Water

Utah to become first U.S. state to ban fluoride in public water systems, sparking debates on health, policy, and individual choice.

Reuters

March 11, 2025

FDA's New Pulse Oximeter Guidance: Stricter Standards, Ongoing Challenges

The FDA's 2025 pulse oximetry guidance introduces stricter accuracy standards, larger study cohorts, and objective skin pigmentation assessment to address measurement bias in darker-skinned patients.

Conexiant

March 07, 2025

New Mexico Measles Cases Hit 30, Health Officials Report

A measles outbreak in New Mexico with 30 cases, including a recent measles-related death, raises concerns and challenges vaccine skepticism. U.S. Health Secretary Robert F. Kennedy Jr. faces a critical test.

Reuters

March 07, 2025

FDA Approves First Xolair Biosimilar

New interchangeable treatment option Omlyclo now available for patients with allergic asthma, chronic hives, nasal polyps, and food allergies; carries same boxed warning for anaphylaxis as original medication.

Conexiant

March 06, 2025

FDA Approves First Needle-Free Epinephrine for Kids

FDA approves neffy 1 mg, the first needle-free intranasal epinephrine spray for pediatric anaphylaxis.

Conexiant

March 05, 2025

FDA Monthly Round-Up: Key February Updates

February's FDA approvals feature advancements in cardiology, neurology, infectious diseases, and rare disorders, including the first trials for genetically modified pig kidney transplants and novel treatments for Parkinson’s disease and spinal muscular atrophy.

Conexiant